Interpretation Extracorporal shock-wave therapy appears to be a supplement for the treatment of chronic Achilles tendinopathy.
malalignment by arch support, stretching exercises, and eccentric training combined with non-steroidal anti-inflammatory pain killers are the standard treatment regimen (Wilson and Best 2005) . However, there is little evidence to support any effect of these modalities (McLauchlan and Handoll 2001) .
Extracorporal shock-wave therapy (ESWT), originally used for treatment of renal stones, has become popular in the last decade for treatment of different soft tissue disorders including calcifying tendinopathy in the rotator cuff, humeral epicondylitis, and plantar fasciitis (Haake et al. 2001a , Ogden et al. 2001 , Chung and Wiley 2002 , Gerdesmeyer et al. 2003 , Speed et al. 2004 . It is now used worldwide and has been FDA-approved for the treatment of plantar fasciitis. The results have, however, been conflicting regarding calcifying tendinopathy in the rotator cuff, humeral epicondylitis, and plantar fasciitis (Rompe et al. 1997 , Boddeker et al. 2001 , Gross et al. 2002 , Hammer et al. 2002 , Pleineret al. 2004 , Chung et al. 2005 . A series of randomized studies on ESWT for soft tissue disorders has been reported (Rompe et al. 1997 , Krishek et al. 1998 , Loew et al. 1999 , Rompe et al. 2001 , Haake et al. 2001a , b, Gross et al. 2002 , Hammer et al. 2002 , Gerdesmeyer et al. 2003 , Pleiner et al. 2004 , Chung et al. 2005 , Costa et al. 2005 , with only 4 reporting significant effect of ESWT (Rompe et al. 1997 , Krishek et al. 1998 , Loew et al. 1999 , Gerdesmeyer et al. 2003 , and there has only been one randomized study for chronic achilles tendinopathy (Costa et al. 2005) . ESWT was introduced for chronic Achilles tendinopathy in 2 uncontrolled (Perlick et al. 2002 , Lakshmanan et al. 2004 ) and 1 controlled (Furia 2005) series. The results of these studies are strongly conflicting. Some authors included training and others not. Since eccentric training has documented effect (Alfredson and Lorentzon 2000) , other conservative treatments should be introduced as a supplement.
In this double-blind, randomized trial, we investigated the effects of supplementary ESWT in enhancing recovery of Achilles tendinopathy, i.e.
(1) the effect on American Orthopaedic Foot and Ankle Society (AOFAS) score and (2) the effect on pain.
Patients and methods
All patients with chronic symptoms of Achilles tendinopathy for over 3 months-who had full working capacity and who were more than 18 years old and able to comply-were considered candidates for inclusion in the study after giving their informed consent, the aim being to study 48 consecutive patients. The patients were recruited at Aalborg University Hospital. The criteria used for diagnosis af Achilles tendinopathy were as follows: an area of swelling moving with dorsiflexion and platarflexion of the ankle, tenderness in neutral position or slightly plantarflexed, and tenderness exacerberated by dorsiflexion of the ankle.
All patients were given conservative treatment at 4 sessions over 4 weeks and after randomization the patients also received active ESWT or sham ESWT at these 4 sessions. The patients were blinded as to the type of treatment, which was done by a person not involved in the study design. An observer who had been blinded regarding the type of treatment evaluated the outcome.
The conservative treatment and ESWT were given in an outpatient clinic; the former consisted of stretching exercises and eccentric training. Local anesthetics were not used. Following stretching and training, ESWT sham or active treatment was given at 4 sessions once a week. All patients were placed prone, unable to see the machine delivering the ESWT but hearing a ticking sound of therapy. Using Piezoson 100 at each session, 2,000 shots (0.12-0.51 mJ/mm 2 , 50 Hz) of radial shock waves were delivered to the area of swelling and tenderness. The sham dose was 2,000 shots at 0 mJ/mm 2 , 50 Hz. Ultrasound guidance was not used. This treatment protocol was based on the results from 3 randomized trials treating plantar fasciitis (Krischenk 1998 , Haake et al. 2001 , Hammer et al. 2002 where ESWT was applied (100-4,000 shots, 0.08-0.2 mJ/mm 2 ) 3 times with 1 or 2 weeks between each session.
Demographics, AOFAS score and pain were measured before and after treatment. The primary endpoint was AOFAS score, an ankle-hindfoot scale of the American Orthopaedic Foot and Ankle Society measuring function (50 points), pain (40 points), and alignment (10 points) (Kitaoka et al. 1994) . 100 points represent the best possible result. Additional analyses were done on pain using a visual analog scale (VAS). At each visit during treatment and follow-up, AOFAS score and VAS for pain on walking, walking upstairs, working, and running were measured.
From October 2004 through January 2005, 51 patients with Achilles tendinopathy were evaluated for participation in the study (Figure 1) . Thus, 48 patients (28 men) were included in the study, with an average age of 47 (19-80) years. Patient demographics were similar in the two groups (Table 1 ). All patients completed the treatment period. During the 3-month follow-up, 1 patient was excluded due to a knee arthroscopy and 2 patients did not attend the final 3-month follow-up. For these patients, data until censored were included in the analysis. Follow-up of all patients ended in June 2005.
Statistics
The sample size was calculated on the basis of AOFAS score. It was calculated for observations on the interval scale. The trial was powered to detect a difference of 10 in the AOFAS score. Significance was set at 5% and power was set at 90%. The estimated standard deviation of 10 of the AOFAS score was set to be equal to the minimal relevant clinical difference. The number of patients in each group was calculated to be 21. To compensate for non-evaluable patients, we planned to enroll 24 patients in each group. The patients were allocated to the 2 groups according to a computer-generated randomization list concealed in a set of numbered envelopes. After acceptance of the patient, the appropriate numbered envelope was opened; the card inside told if the patient was to be an intervention case or a control case. The inclusion period was expected to last 3-4 months. Results are expressed as mean and standard deviation, and analyzed using repeated-measures analysis of variance test (Matthews et al. 1990 ) with all pairwise multiple comparison procedures (Bonferroni t-test). Analysis of change from before treatment to 3-month follow-up was based on analysis of covariance and expressed as mean and 95% confidence intervals (CIs). Values of p < 0.05 were considered statistically significant. The program Stata 9.2 was used.
The study was approved at the local ethics committee in North Denmark Region (VN2004/31) and was carried out in accordance with the Declaration of Helsinki. The study is registered in www.ClinicalTrials.gov as ON-007-01-RAS.
Results
AOFAS score after treatment increased more over time in the intervention group than in the control group (p = 0.05), from 70 (SD 6.8) to 88 (10) in the Randomized n=48
Not meeting inclusion criteria n=15
Own choice of placebo n=1
Allocated to placebo n=24
Own choice of shockwave therapy n=2
Allocated to shockwave therapy n=24
Received allocated 4 weeks intervention n=24
4 weeks follow-up examination n=24
8 weeks follow-up examination n=23
12 weeks follow-up examination n=22
4 weeks follow-up examination n=23
Lost due to change of address n=1
Lost to follow-up, refused to continue n=1
Excluded due to knee arthroscopy n=1 8 weeks follow-up examination n=23
12 weeks follow-up examination n=23
Received allocated 4 weeks intervention n=24 (Figures 2 and 3) . Better results were seen in the intervention group at 8 and 12 weeks of follow-up (p = 0.01 and p = 0.04, respectively). The analysis was according to intention to treat and involved all patients who were randomly assigned. Estimated marginal means after treatment were 89 (85-95) in the intervention group and 79 (74-85) in the control group, with a mean difference of 10 (3.2-15.8) (p = 0.006). Pain was reduced in both groups, but there was no statistically significant difference between the groups (Figure 4) . A subgroup analysis, which was not preplanned, showed that women had the best outcome at 3 months of follow-up; the AOFAS score was 91 (10) in the intervention group and 77 (18) in the control group (p = 0.05). In men, the AOFAS score at 3 months of follow-up was similar in the 2 groups. We did not find sex differences regarding pain.
Discussion
Treatment of Achilles tendinopathy with ESWT led to a clinically relevant effect, with improvement of the AOFAS score. There was no supplementary effect of ESWT on pain. One possible mechanism for and explanation of our findings would be that ESWT improves function and activity. The pain is not reduced since the patients gradually increase activity to a constant, acceptable level of pain. One reason that might explain why we did not find a significant difference regarding pain may have been the difference in sex ratio, as there were more women in the control group who would have had a lower pain threshold and a lower tolerance to painful stimuli (Keogh et al. 2005 , Ge et al. 2006 , and thus another level of function and activity. Surprisingly, in our study it was the women who benefited from ESWT. Interaction between the sex of experimenters and subjects is also a possible explana- tion. One study has shown tolerance of higher pain intensities in subjects tested by female experimenters (Kallai et al. 2004 ). In our study, the experimenters were women. The AOFAS score may not be appropriate for evaluation of treatment of Achilles tendinopathy. The system includes a score for alignment, which does not change with any treatment of the Achilles tendon. Furthermore, the AOFAS system includes a score for subtalar range of movement and stability of ankle and hindfoot, which may not change. When the primary score is high, the possible gain in score up to 100 is low, thereby reducing the sensitivity of the intervention group to treatment compared to the control group in this study. When there is an upper limit of the score, it may be more realistic to use a ratio of gained increase in relation to possible increase.
Weaknesses of our study may be that the ESWT treatment area was too small compared to the extent of the tendinopathy, that precise location of the lesion was not documented, or that an energy level that was too low was used. Factors that may have influenced the results are too small treatment area, too low energy level and possible up to 1.1 mJ/mm 2 , ultrasound guidance to localize inflammatory tissue, and improved technology.
The majority of randomized trials comparing ESWT to placebo could not find an effect of ESWT (Table 2) . Area of treatment, whether or not guidance was used, and energy level may at least partly explain this. One study on calcifying tendinopathy in the rotator cuff found surgery to be superior to ESWT (Rompe et al. 2001b) , and another randomized study found steroid injection to be superior to ESWT for plantar fasciopathy (Porter and Shadbolt 2005) .
Regarding lateral epicondylitis, four randomized trials have been published (Rompe et al. 1997 , Chung et al. 2005 , Spacca et al. 2005 , with only two (Rompe et al. 1997 , Spacca et al. 2005 showing an effect. The trials gave conflicting results and a Cochrane review (McLauchlan and Handoll 2001) concluded before the publication of the third and fourth trials (Chung et al. 2005 , Spacca et al. 2005 ) that further trials were needed to clarify the value of ESWT for lateral elbow pain. The third trial showed no effect. Randomized studies on the effect of ESWT in the treatment of plantar heel pain (Krischek et al. 1998 , Hammer et al. 2002 and calcifying shoulder tendonitis (Rompe et al. 1997 , Loew et al. 1999 , Haake et al. 2001a , Gross et al. 2002 , Gerdesmeyer et al. 2003 , Pleiner et al. 2004 have also yielded conflicting results. One randomized study (Costa et al. 2005) , 2 uncontrolled studies (Perlick et al. 2002 , Lakshmanan et al. 2004 , and 1 controlled (Furia 2005) trial included ESWT in the treatment of Achilles tendinopathy. In the series from Germany, 29 of 40 patients showed satisfactory results (Perlick et al. 2002) . In the series from the UK, 16 affected tendons in 15 patients improved-as measured by the AOFAS score and the Visa A score systems (Lakshmanan et al. 2004) . The randomized study (Costa et al. 2005) , which was published while we were conducting our study, indicated no effect of ESWT. In that study, the treatment group was 10 years younger on average than the placebo group.
The data were incomplete, since 9 patients failed to attend the 1-month follow-up and 6 patients failed to attend the 1-year follow-up. The authors did find a reduced pain score in the treatment group, but this was not statistically significant.
Four uncontrolled trials (Lohrer et al. 2002 , Perlick et al. 2002 , Lakshmanan et al. 2004 , Furia 2005 have found an effect of ESWT on chronic Achilles tendinopathy.
Traditionally, a chronic painful achilles tendon has been referred to as Achilles tendonitis because of pain, swelling, and increased vascularity. However, recent studies have concluded that little or no inflammation is involved (Alfredson et al. 1999 , Riley 2004 ). Modern ultrasound-based imaging technology shows that chronic painful Achilles tendons are characterized by increased blood flow and perfusion, called neo-vascularization, intratendinously and peritendinously (Öhberg and Alfredson 2004) . This new vascularization is most likely an attempt to repair generative lesions on the tendon. Such lesions may be due to tissue hypoxia or repetitive microtrauma, frequently described as overused pathologies. Tissue hypoxia may result from increasing age, vascular degeneration, physical disuse, or trauma (Riley 2004) . In 60% of patients with Achilles tendinopathy, malalignment has been found, most often limited mobility of the subtalar joint and limited range of motion in the ankle joint. In addition, various deformities of the forefoot and increased foot pronation have been found to be associated with Achilles tendinopathy. Other contributory factors are leg length discrepancy, muscle weakness and imbalance, and training errors (Paavola et al. 2002) . Several diseases correlate with increased risk of tendinopathy: diabetes mellitus, renal disease, and rheumatological diseases amongst others. Increased body weight and a sedentary lifestyle coupled to the physical demands of certain occupations or sporting activities may account for the increased incidence of tendon rupture in recent times (Riley 2004) . The traditional nonoperative interventions include relative rest, avoiding painful aggravating activities, non-steroid anti-inflammatory drugs, customized shoes and heel lifts, stretching exercises, and eccentric calf muscle training. The results of these treatments are often unsatisfactory, however. Corticosteroid injection at the site of the lesion has not been recommended because of its possible tendonweakening effect. The effect on neovascularization has been studied most intensively for eccentric training, which has been demonstrated to reduce revascularizations effectively (Öhberg and Alfredson 2004) . In pioneer studies, sclerosing with polydocanol and steroid administered by intratendinous injection and iontophoreasis have been found to be effective (Öhberg and Alfredson 2002 ). ESWT appears to be a clinically relevant supplement to conservative treatment of tendinopathy. Currently, however, there is no convincing evidence for recommendation of ESWT. Further studies should be done to explore the effects of improved technology such as higher energy per area, greater treatment area, and-if possible-one session of treatment. Another important methodological issue is the importance of gender and activity. A scoring system concentrating on handicap, function, and activity may be more relevant than systems that cover pain and alignment. The observations that responsivity may be influenced by the genders of the subject and experimenter (Kallai et al. 2004 , Ge et al. 2006 should be addressed in future trials.
ESWT is being widely used, but it has only been FDA-approved for the treatment of plantar fasciitis. The worldwide use of ESWT for treatment of muscular-skeletal complaints is still under debate.
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